FCM
DNLI icon

Flinton Capital Management’s Denali Therapeutics DNLI Stock Holding History

Flinton Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$7K Hold
432
– – ﹤0.01% 887
2019
Q2 		$9K Hold
432
– – ﹤0.01% 877
2019
Q1 		$10K Hold
432
– – ﹤0.01% 864
2018
Q4 		$9K Buy
+432
New +$7.84K ﹤0.01% 849

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Flinton Capital Management's DNLI Position: Q3 2019 in Review

Flinton Capital Management held its Denali Therapeutics (DNLI) position steady in Q3 2019 at 432 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Flinton Capital Management first reported a position in DNLI in Q4 2018 and has held it in 4 quarters since. The position peaked at $10K in Q1 2019. 118 funds tracked by Wall St. Rank hold DNLI as of Q3 2019.

  • Flinton Capital Management held 432 shares of Denali Therapeutics worth $7K as of Q3 2019.
  • Flinton Capital Management left its Denali Therapeutics share count unchanged in Q3 2019.
  • Denali Therapeutics made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #887 holding.
  • Flinton Capital Management first reported a position in Denali Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Flinton Capital Management's Denali Therapeutics position peaked at $10K in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.